Beneficial ownership — 13D / 13G
87,281 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.
Coverage begins December 2024, when the SEC required these schedules to be filed as structured XML.
| Reporting person | Issuer | Schedule | % of class | Event date | Filed |
|---|---|---|---|---|---|
| Neeraj Agrawal | AMPL Amplitude, Inc. | 13G/A | 10.9% | Dec 31, 2023 | 2y |
| Strategic Value Investors LP | MRBK Meridian Corp | 13G/A | 5.8% | Dec 31, 2023 | 2y |
| M3 Funds, LLC | SWKHL SWK Holdings Corp | 13G/A | 6.16% | Dec 31, 2023 | 2y |
| K2 HealthVentures Equity Trust LLC | MTEM Molecular Templates, Inc. | 13G/A | 9.99% | Dec 31, 2023 | 2y |
| Omega Fund VI, L.P. | LXEO Lexeo Therapeutics, Inc. | 13G | 8.1% | Dec 31, 2023 | 2y |
| GenScript Biotech Corporation | LEGN Legend Biotech Corp | 13G/A | 47.99% | Dec 31, 2023 | 2y |
| GLAZER CAPITAL, LLC | VMCAF Valuence Merger Corp. I | 13G/A | 11.28% | Dec 31, 2023 | 2y |
| Andrew Shape | SWAG Stran & Company, Inc. | 13G/A | 19.2% | Dec 31, 2023 | 2y |
| AQR CAPITAL MANAGEMENT LLC | KYCH Keyarch Acquisition Corporation Ordinary Shares | 13G/A | 1.48% | Dec 31, 2023 | 2y |
| Granahan Investment Management, LLC | MGNI Magnite, Inc. | 13G/A | 4.88% | Dec 31, 2023 | 2y |
| Point72 Asset Management, L.P. | VTGN Vistagen Therapeutics, Inc. | 13G/A | 3% | Dec 31, 2023 | 2y |
| Invenomic Capital Management LP | LEXX Lexaria Bioscience Corp. | 13G/A | 7.12% | Dec 31, 2023 | 2y |
| RIVERNORTH CAPITAL MANAGEMENT, LLC | GCTS GCT Semiconductor Holding, Inc. | 13G | 9.52% | Dec 31, 2023 | 2y |
| T. Rowe Price Investment Management, Inc. | CSW Csw Industrials, Inc. | 13G | 7.3% | Dec 31, 2023 | 2y |
| BIOTECHNOLOGY VALUE FUND L P | TYRA Tyra Biosciences, Inc. | 13G/A | 6.4% | Dec 31, 2023 | 2y |
| Nan Shan Life Insurance Co., Ltd. | KREF KKR Real Estate Finance Trust Inc. | 13G/A | 4.44% | Dec 31, 2023 | 2y |
| FPR PARTNERS LLC | VISN Vistance Networks, Inc. | 13G/A | 8.8% | Dec 31, 2023 | 2y |
| PRICE T ROWE ASSOCIATES INC /MD/ | RARE Ultragenyx Pharmaceutical Inc. | 13G/A | 4.2% | Dec 31, 2023 | 2y |
| AMERIPRISE FINANCIAL INC | STVN Stevanato Group S.p.A. | 13G/A | 3.22% | Dec 31, 2023 | 2y |
| First Trust Capital Management L.P. | ROSS Ross Acquisition Corp II | 13G | 9.85% | Dec 31, 2023 | 2y |
| McIntyre Dee Ann | UFCS United Fire Group Inc | 13G/A | 11.9% | Dec 31, 2023 | 2y |
| CVI Investments, Inc. | EVFM Evofem Biosciences, Inc. | 13G/A | 0.9% | Dec 31, 2023 | 2y |
| Gleb Budman | BLZE Backblaze, Inc. | 13G/A | 4.8% | Dec 31, 2023 | 2y |
| Brookfield Oaktree Holdings, LLC | ECDA ECD Automotive Design, Inc. | 13G/A | 1.14% | Dec 31, 2023 | 2y |
| (VOLUNTARY) Kim A. Rivers | TRLV Trulieve Cannabis Corp. | 13G/A | 9.55% | Dec 31, 2023 | 2y |
| Cormorant Asset Management, LP | JBIO Jade Biosciences, Inc. | 13G/A | 4.38% | Dec 31, 2023 | 2y |
| T. Rowe Price Investment Management, Inc. | AMPL Amplitude, Inc. | 13G | 8.2% | Dec 31, 2023 | 2y |
| Fort Baker Capital Management LP | OKLO Oklo Inc. | 13G | 5.85% | Dec 31, 2023 | 2y |
| Brookfield Oaktree Holdings, LLC | EMAT Evolution Metals & Technologies Corp. | 13G/A | 0% | Dec 31, 2023 | 2y |
| Radcliffe Capital Management, L.P. | NKGN NKGen Biotech, Inc. Common Stock | 13G/A | 0% | Dec 31, 2023 | 2y |
| First Trust Capital Management L.P. | GAQ Generation Asia I Acquisition Limited Class A Ordinary Shares | 13G | 9.95% | Dec 31, 2023 | 2y |
| Werner Capital LLC | ENFN Enfusion, Inc. | 13G/A | 5.04% | Dec 31, 2023 | 2y |
| BIOTECHNOLOGY VALUE FUND L P | PYXS Pyxis Oncology, Inc. | 13G/A | 0% | Dec 31, 2023 | 2y |
| Harvey Partners, LLC | MTRX Matrix Service Co | 13G/A | 5.2% | Dec 31, 2023 | 2y |
| ARMISTICE CAPITAL, LLC | RKTO Rocket One Inc. | 13G/A | 4.99% | Dec 31, 2023 | 2y |
| Atlas Merchant Capital LLC | IPVF InterPrivate III Financial Partners Inc. | 13G/A | 0% | Dec 31, 2023 | 2y |
| First Trust Capital Management L.P. | PLAO Patria Latin American Opportunity Acquisition Corp. Class A Ordinary Shares | 13G | 9.93% | Dec 31, 2023 | 2y |
| Par Sanda | SRG Seritage Growth Properties | 13G/A | 4.11% | Dec 31, 2023 | 2y |
| Atalaya Capital Management LP | GAQ Generation Asia I Acquisition Limited Class A Ordinary Shares | 13G/A | 6.9% | Dec 31, 2023 | 2y |
| ARMISTICE CAPITAL, LLC | AGIO Agios Pharmaceuticals, Inc. | 13G/A | 6.31% | Dec 31, 2023 | 2y |
| Nathan Leight | YTRA Yatra Online, Inc. | 13G/A | 5.59% | Dec 31, 2023 | 2y |
| PERCEPTIVE ADVISORS LLC | VRCA Verrica Pharmaceuticals Inc. | 13G/A | 16.9% | Dec 31, 2023 | 2y |
| Sandia Investment Management LP | OPTX Syntec Optics Holdings, Inc. | 13G/A | 0.93% | Dec 31, 2023 | 2y |
| Lincoln Park Capital Fund, LLC | XFOR X4 Pharmaceuticals, Inc | 13G/A | 0.95% | Dec 31, 2023 | 2y |
| AWM Investment Company, Inc. | IPWR Ideal Power Inc. | 13G/A | 9.99% | Dec 31, 2023 | 2y |
| Ares Trading SA | PGEN Precigen, Inc. | 13G/A | 8.3% | Dec 31, 2023 | 2y |
| RA CAPITAL MANAGEMENT, L.P. | NSTG NanoString Technologies, Inc. | 13G/A | 0% | Dec 31, 2023 | 2y |
| Radcliffe Capital Management, L.P. | LIVB LIV Capital Acquisition Corp. II Class A Ordinary Shares | 13G/A | 0% | Dec 31, 2023 | 2y |
| EVR Research LP | SSTI Soundthinking, Inc. | 13G/A | 4.8% | Dec 31, 2023 | 2y |
| T. Rowe Price Investment Management, Inc. | AVY Avery Dennison Corp | 13G | 5.3% | Dec 31, 2023 | 2y |